<DOC>
	<DOCNO>NCT00077181</DOCNO>
	<brief_summary>Drugs use chemotherapy , cytarabine , work different way stop cancer cell divide stop grow die . 3-AP may help cytarabine kill cancer cell make sensitive drug . This phase I trial study side effect best dose 3-AP give high-dose cytarabine treat patient advanced hematologic malignancy</brief_summary>
	<brief_title>3-AP High-Dose Cytarabine Treating Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose 3-AP ( Triapine ) administer high-dose cytarabine patient advance hematologic malignancy . SECONDARY OBJECTIVES : I . Determine clinical activity regimen patient . II . Determine effect treatment 3-AP ( Triapine ) intracellular level cytarabine patient . OUTLINE : This dose-escalation study 3-AP ( Triapine ) . Patients receive high-dose cytarabine IV 2 hour day 1-5 3-AP ( Triapine ) IV 2 hour day 2-5 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient stratum receive escalating dos 3-AP ( Triapine ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 2 year . PROJECTED ACCRUAL : A total 6-48 patient ( 3-24 per stratum ) accrue study within 15-24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Histologically confirm diagnosis 1 follow hematologic malignancy : Relapsed refractory acute myeloid leukemia ( AML ) Relapsed refractory acute lymphoblastic leukemia Secondary AML , include AML arise antecedent hematologic disease , myelodysplastic syndrome myeloproliferative disorder OR therapyrelated AML Chronic myeloid leukemia accelerate blast phase Refractory standard therapy standard therapy exist No known brain metastasis Performance status CALGB 02 Performance status Karnofsky 60100 % No G6PD deficiency Bilirubin &lt; 2.0 mg/dL ( unless due Gilbert 's syndrome ) AST ALT &lt; 2.5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No pulmonary disease require oxygen Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition study drug No neuropathy No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness No concurrent biologic agent At least 72 hour since prior hydroxyurea At least 2 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) No concurrent chemotherapy At least 2 week since prior radiotherapy No concurrent radiotherapy Recovered prior therapy At least 4 week since prior investigational agent No concurrent investigational therapy No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>